Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Chemotherapy for Adjuvant ESCC
NCT05637268Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2020
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: 3-year Disease-Free Survival rate. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05637268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05637268.